You got a letter from your insurance company. Starting next month, your Remicade is being replaced with something called Inflectra (or Renflexis, or Avsola). The letter says these are “biosimilars” and are “clinically equivalent.” But you’ve been stable on Remicade for two years. Your Crohn’s is finally quiet. Your RA is manageable. And now someone is swapping your medication without asking you.
If you’re feeling a little betrayed, a little anxious, and a lot confused, that is completely understandable. The letter makes it sound simple. It isn’t always simple emotionally, even when the clinical science says it should be.
Here’s what we’re going to do in this article. We’re going to walk through exactly what biosimilars are, how they’re different from generics (they aren’t the same thing), why the FDA considers them interchangeable with the brand, what the clinical evidence actually says about switching, and what to do if you’re nervous. No hype, no pharma spin, no pretending the transition is emotionally easy. Just the real answers from pharmacists who handle these switches every day.
| Switched to a biosimilar without warning? Our pharmacists explain exactly what’s changing, review your coverage, and coordinate with your doctor so you don’t have to. ▶ Call (949) 555-0100 · Request a Consult |
What Is a Biosimilar, Exactly?
A biosimilar is a biologic medication that is highly similar to an already-approved biologic drug, with no clinically meaningful differences in terms of safety, purity, or potency. That’s the FDA’s definition, and every word in it matters.
Let’s unpack that with an analogy. Think of a brand-name biologic like Remicade as a piece of sourdough bread baked in a specific bakery with a specific starter, specific flour, and a specific oven. A biosimilar is the same recipe baked in a different bakery. The ingredients are the same, the end product looks and tastes and nourishes the same, but because it’s a living process (biologic means “made from living cells”), no two loaves are ever atom-for-atom identical.
That’s different from a generic medication, which is what you get when a small-molecule drug like ibuprofen or lisinopril goes off-patent. Generics are chemically identical to their brand. Biosimilars are similar to their reference product, not identical, because the molecules are too large and complex (hundreds of thousands of atoms, folded into specific 3D shapes) to copy perfectly.
| 💡 The quick version Generic = chemically identical copy of a simple drug. Biosimilar = highly similar copy of a complex biologic, proven through extensive testing to work the same way. Both save money. Only biosimilars apply to drugs like Remicade, Humira, and Rituxan. |
Meet Your Options: Inflectra, Renflexis, and Avsola
Remicade is the brand name for infliximab, a TNF-alpha inhibitor used to treat Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It was first FDA-approved in 1998 and was the reference biologic for every infliximab biosimilar that followed.
There are currently three FDA-approved infliximab biosimilars commonly used in the United States. Here’s how they compare:
| Medication | Approved | Maker | Non-proprietary Name |
|---|---|---|---|
| Remicade (reference) | 1998 | Janssen | infliximab |
| Inflectra | 2016 | Pfizer | infliximab-dyyb |
| Renflexis | 2017 | Organon / Merck | infliximab-abda |
| Avsola | 2019 | Amgen | infliximab-axxq |
You may notice the four-letter suffix on each biosimilar (dyyb, abda, axxq). That’s an FDA naming convention to distinguish biosimilars from one another and from the reference product. The suffix is randomly assigned and doesn’t signal anything about quality, potency, or ranking. It’s purely an identifier.
All three biosimilars are approved for the same conditions as Remicade (with some differences in pediatric indications that your doctor and pharmacist can confirm). All three are given by IV infusion at the same dose and schedule. All three have to meet the FDA’s rigorous biosimilar standards, which we’ll get into next.
How Does the FDA Approve a Biosimilar?
This is the part that quiets most people’s concerns once they understand it. Biosimilar approval is not a paper-shuffle exercise. The FDA requires three layers of evidence.
1. Analytical similarity (structural and functional)
Manufacturers run hundreds of analytical tests comparing the biosimilar to the reference product at the molecular level. They compare protein structure, folding, glycosylation patterns, potency, binding affinity, and immunogenicity markers. The biosimilar has to match the reference product within narrow tolerances, tighter than the batch-to-batch variation the reference product itself shows.
2. Non-clinical (animal) studies
Pharmacology and toxicology testing in animal models to confirm the biosimilar behaves the same way in a living system.
3. Clinical studies in humans
Head-to-head trials in patients, comparing the biosimilar to the reference product for pharmacokinetics (how the drug moves through your body), pharmacodynamics (what it does once it’s there), efficacy (does it treat the condition), safety, and immunogenicity (do patients develop antibodies against it). The trials include “switching studies” where patients are randomized between staying on the reference product and transitioning to the biosimilar, and outcomes are tracked for a year or more.
| ⚠️ One important nuance The FDA uses a concept called extrapolation. If a biosimilar is studied in one condition (say, rheumatoid arthritis) and shown equivalent to the reference product, the FDA can approve it for other conditions the reference product treats (like Crohn’s) without requiring separate trials for each one, as long as the mechanism of action is the same across those conditions. Some patients find this unsettling. The FDA’s position is that the mechanism is what matters, and the totality of the analytical and clinical evidence supports extrapolation. It’s a scientific argument. Ask your doctor if you want to dig into the specifics for your condition. |
Are Biosimilars Actually as Safe and Effective as Remicade?
The clinical answer, based on over a decade of real-world use and dozens of peer-reviewed studies, is yes. Here’s what the evidence shows:
- Similar efficacy. Response rates, remission rates, and clinical outcomes are statistically equivalent between infliximab biosimilars and Remicade across the major indications.
- Similar safety profile. Rates of infusion reactions, infections, and serious adverse events track closely with the reference product.
- Similar immunogenicity. The rate at which patients develop anti-drug antibodies (a concern unique to biologics) is comparable between biosimilars and Remicade.
- Real-world switching data. Large European and U.S. healthcare systems have been switching patients from Remicade to biosimilars since 2016. Studies following thousands of patients show retention rates, disease control, and side effect profiles that are not meaningfully different from staying on the reference product.
That said, “statistically equivalent” doesn’t mean “identical experience for every single patient.” A small percentage of people report that a biosimilar doesn’t feel the same to them. Some of that is likely biology; some is likely the nocebo effect (expecting a worse outcome and then perceiving one). Both are real, and both are worth taking seriously. More on what to do in that case below.
| Starting on a biosimilar? Or considering switching back? A specialty pharmacist can walk you through your options, coordinate with your doctor, and handle the insurance conversation for you. ▶ Talk to a Pharmacist · (949) 555-0100 |
Why Did My Insurance Switch Me Without Asking?
The short answer: money. Biosimilars cost less to manufacture and are priced 15 to 35 percent below the reference product. Insurance plans and pharmacy benefit managers (PBMs) negotiate preferred pricing with biosimilar makers, and in exchange they move the biosimilar to a preferred tier on their formulary. Members on the non-preferred brand either pay higher out-of-pocket costs or get switched automatically.
The slightly longer answer is that formulary management is a standard cost-control mechanism. Your plan isn’t singling you out. They’re making a systemic decision to reduce drug spending, which (in theory) keeps premiums lower for everyone. Whether you agree with that logic or not, the switch is usually not negotiable at the individual level unless you or your doctor document a medical reason the biosimilar won’t work for you.
What about “non-medical switching”?
That’s the term patient advocacy groups use when an insurer forces a switch for financial reasons rather than clinical ones. It’s controversial. Some states have passed laws requiring prescriber notification before a switch. Major GI, rheumatology, and dermatology societies have taken official positions on when switching is appropriate and when it shouldn’t be forced. If you want to push back on a forced switch, the first step is a conversation with your prescribing doctor. They can submit a letter of medical necessity if there’s a clinical reason to stay on the reference product.
What Does “Interchangeable” Mean?
You may see the word “interchangeable” on your paperwork. This is a specific FDA designation, separate from biosimilar status.
- All biosimilars are highly similar to the reference product and can be prescribed by your doctor in place of the reference product.
- An “interchangeable” biosimilar meets an additional, higher standard. It’s been shown to produce the same clinical result as the reference product in any given patient, and (in most states) a pharmacist can substitute it for the reference product without requiring a new prescription from the doctor, similar to how generics work at a retail pharmacy.
As of this writing, no infliximab biosimilar has received the interchangeable designation. That means your doctor has to actively prescribe Inflectra, Renflexis, or Avsola — a pharmacist can’t swap them without a new script. In practice, the insurance company’s formulary change prompts your doctor to update the prescription, and the specialty pharmacy fills it as written.
| ✓ Bottom line on the switch If you’re being switched from Remicade to an infliximab biosimilar, your doctor has to actively write the new prescription. That’s your built-in clinical safeguard. Your specialty pharmacy confirms the change with the prescriber before any product swap happens. |
What If the Biosimilar Doesn’t Work for Me?
Here’s what we tell every patient who’s about to switch. Give it a fair chance, track your response, and speak up if something feels off. Specifically:
- Keep a symptom diary for the first 3 to 6 months. Note infusion reactions, disease flares, fatigue, joint pain, GI symptoms, anything relevant to your condition. Date everything.
- Don’t attribute normal fluctuation to the switch. Chronic conditions have good weeks and bad weeks regardless of what medication you’re on. A single rough week two months in probably isn’t the biosimilar failing.
- Talk to your doctor if you see a real trend. Sustained loss of response, new or worse infusion reactions, or measurable disease activity (lab markers, imaging, symptom severity) are all legitimate reasons to revisit your treatment plan.
- Switching back is possible but not automatic. If the biosimilar truly isn’t working, your doctor can submit a letter of medical necessity to your insurer. Your specialty pharmacy can provide documentation of the timeline, dosing history, and side effect log to support the appeal.
How a Specialty Pharmacy Makes Biosimilar Switches Easier
A biosimilar switch touches three things at once: your medication, your insurance, and your infusion schedule. Handling all three on your own is a lot. This is exactly where a specialty pharmacy earns its keep.
Before the switch
- We verify the new prescription with your doctor’s office
- We run the benefits and confirm your out-of-pocket cost under the new formulary
- We coordinate with your infusion center so your next appointment uses the correct product
- We explain the specific differences (if any) between what you were getting and what’s coming
During the transition
- We monitor your first few infusions more closely
- We answer clinical questions 24/7 from our pharmacist team
- We document any side effects or response changes in your record
After the switch
- We flag any concerning patterns to your prescriber
- If a switch-back is warranted, we help assemble the medical necessity appeal
- We hunt for co-pay assistance or foundation grants if the new cost structure is a burden
| Questions about Inflectra, Renflexis, or Avsola? Our pharmacists have handled thousands of biosimilar transitions. We’ll answer every question before your next infusion. ▶ Contact River’s Edge · (949) 555-0100 |
Frequently Asked Questions
Q: Are biosimilars cheaper than Remicade?
Yes, typically 15 to 35 percent cheaper at the wholesale level. Whether you personally pay less depends on your insurance. Many plans moved biosimilars to a preferred tier with lower co-pays, but every plan is different. Ask your specialty pharmacy to run a benefits check so you know exactly what your cost will be.
Q: Will my infusion take the same amount of time?
Yes. Dosing, infusion rate, and appointment length are the same for Remicade and all three infliximab biosimilars. You should expect a 2- to 3-hour infusion plus a short monitoring period, just like before.
Q: Do biosimilars have the same side effects as Remicade?
Yes, the side effect profile is essentially identical. Infusion reactions, increased infection risk, headaches, and the other known infliximab side effects apply to biosimilars the same way. Your infusion team will monitor you the same way, and you should report anything unusual the same way.
Q: Can I refuse the switch and stay on Remicade?
Sometimes. If you and your doctor believe there’s a medical reason you should stay on the reference product (for example, a prior failure or contraindication to a biosimilar, though this is rare), your doctor can submit a letter of medical necessity. The insurer isn’t obligated to agree, but appeals do succeed. Your specialty pharmacy can help assemble the documentation.
Q: What’s the difference between Inflectra, Renflexis, and Avsola?
Clinically, there is no meaningful difference. All three are FDA-approved infliximab biosimilars with equivalent safety and efficacy compared to Remicade. The differences are the manufacturer, the price negotiated with your insurer, and the formulary tier. Your plan decides which one you get; your outcomes should be the same either way.
Q: If I switch from Remicade to a biosimilar, can I switch back later?
Yes, but it’s not automatic. Your doctor has to prescribe Remicade again, and your insurer has to approve it — usually requiring evidence that the biosimilar didn’t work for you. Keep good records of any issues during the biosimilar trial so your medical necessity appeal has documentation to stand on.
| 💡 Schema markup note for developers Wrap the entire FAQ section in FAQPage schema, with each question as a Question entity and each answer as an Answer entity. Include at the page level a separate Drug schema for Remicade, Inflectra, Renflexis, and Avsola with their RxNorm codes. Author should be Person schema with medicalSpecialty: Pharmacy. |
The Takeaway
A biosimilar switch can feel like a loss of control. That feeling is valid. But the clinical reality is that infliximab biosimilars have a decade of real-world evidence showing they work the same as Remicade for the vast majority of patients. The machinery around the switch (insurance formulary, prescription rewrite, specialty pharmacy logistics) is what often feels chaotic, not the medicine itself.
If you are staring at a letter from your insurer right now, take a breath. Call your specialty pharmacist before you call your insurance company. We will translate the letter, check your coverage, coordinate with your doctor, and tell you exactly what’s changing and what isn’t. The goal is the same as it’s always been: keep you on the therapy that keeps you well.